Olga Vladimirovna Kondratenko

Olga Vladimirovna Kondratenko

Auto-generated profile, based on publicly available information

Olga Vladimirovna Kondratenko

Samara State Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
SASergey Avdeev
Sergey Avdeev
YMYu. L. Mizernitskiy
Yu. L. Mizernitskiy
Aleksander V. PolyakovAleksander V. Polyakov
Aleksander V. Polyakov
MCMarina Chernukha
Marina Chernukha
ЮМЮ. Л. Мизерницкий
Ю. Л. Мизерницкий
Primary ciliary dyskinesia (PCD) is a rare hereditary disease from the group of ciliopathies, which is based on a defect in the cilia ultrastructure of the respiratory epithelium and similar structures (sperm flagella, villi of the fallopian tubes, ventricular ependyma, etc.), leading to motor function impairment. The prevalence of the disease varies significantly around the world and is not known reliably in the Russian Federation.The aim of the review was to analyze literature data on modern approaches to the diagnosis and treatment of PCD.Methodology. The data of 90 articles and the opinions of experts providing care to patients with PCD were used.Results. The classic manifestations of PCD depend on age. The leading manifestations of the disease in patients with PCD are recurrent inflammatory diseases of the upper and lower respiratory tract (bronchitis, pneumonia), with the formation of bronchiectasis, damage to the ENT organs (chronic rhinitis, rhinosinusitis, nasal polyposis, repeated otitis media, progressive hearing loss). Currently, there is no single method which could serve as a “gold” standard for diagnosing PCD. The diagnosis of PCD is based on the characteristic clinical picture in combination with the results of special tests (nitric oxide in exhaled air, DNA diagnostics, high-speed video microscopy, transmission electron microscopy). The genetic diagnostics has not been developed sufficiently in the global practice yet and is unavailable in our country. The approach to the treatment of a patient with PCD should be multidisciplinary due to multiple organ lesions. According to the European consensus, the goal of PCD therapy is to restore or maintain normal lung function. There have been no randomized trials of treatment for PCD, and therefore all treatment recommendations are based on very low-level evidence or extrapolated from cystic fibrosis guidelines. Recommendations on mucolytic, antibacterial and anti-inflammatory therapy of PCD are given with consideration for the international and domestic experience.Conclusion. The development of a new version of clinical guidelines containing up-to-date relevant information will improve the diagnosis and treatment of PCD in the Russian Federation.

27 May 2022 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
ABAlexander A. Baranov
Alexander A. Baranov
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
SKSergei I. Kutsev
Sergei I. Kutsev
SASergey Avdeev
Sergey Avdeev
EPElena V. Polevichenko
Elena V. Polevichenko
ЭСЭ. В. Синьков
Э. В. Синьков
The problem of timely diagnosis and proper management of patients with cystic fibrosis is crucial not only in our country, but throughout the world. Experts of the Union of Pediatricians of Russia have considered various issues of etiology, pathogenesis, epidemiology, diagnosis, and treatment of this genetic disease in a modern light. Particular attention was paid to screening methods for early diagnosis of cystic fibrosis. The principles of complex therapy were justified, including rational use of antibacterial and mucolytic drugs and enzyme replacement therapy that significantly determine the disease prognosis.

21 May 2022 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
JBJulia Bocharova
Julia Bocharova
TSTatiana Savinova
Tatiana Savinova
ALA. V. Lyamin
A. V. Lyamin
OKO. V. Kondratenko
O. V. Kondratenko
SPS. V. Polikarpova
S. V. Polikarpova
ICIgor Chebotar
Igor Chebotar
Stenotrophomonas maltophilia is a common opportunistic microorganism and an important respiratory pathogen in cystic fibrosis (CF). The aim of this study was to determine antimicrobial resistance phenotypes, sequence-types (ST) and genetic determinants of antibiotic resistance in S. maltophilia strains recovered from CF patients in Russia. S. maltophilia isolates recovered from 170 CF patients were analyzed. Minimum inhibitory concentrations of antibacterial agents were determined using Sensititre Gram Negative GNX2F plates and the results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) criteria. Whole-genome sequencing (WGS) was performed on MGISEQ-2000 platform. SPAdes software, Galaxy, ResFinder, Integrall and PubMLST were used for analysis of WGS data. S. maltophilia strains were identified from 24/170 (14%) CF patients. In total, 25 isolates were detected, two strains were isolated from the same patient. The isolates belonged to 17 different STs, including 5 new STs; ST4 was the most prevalent ST. Resistance to ceftazidime was observed in 60% of strains, to ticarcillin-clavulanate - in 32%, to levofloxacin - in 24%, to trimethoprim/sulfamethoxazole - in 12% of strains. All isolates were susceptible to minocycline. All ST4 isolates were resistant or intermediate to ceftazidime and ticarcillin-clavulanate. In two isolates, the sul1 gene was detected. In one isolate, sul1 was part of a class 1 integron. The detected integron also contained the blaGES-7 and aac(6’)-Ib-cr genes. The ST4 sequence-type was the most prevalent ST among S. maltophilia strains recovered from CF patients in Russia. Antibiotic resistance genes, including sul1, blaGES-7, aac(6’)-Ib-cr, were detected in single strains.

18 October 2021 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
JBJulia Bocharova
Julia Bocharova
TSTatiana Savinova
Tatiana Savinova
ALA. V. Lyamin
A. V. Lyamin
OKO. V. Kondratenko
O. V. Kondratenko
SPS. V. Polikarpova
S. V. Polikarpova
ICIgor Chebotar
Igor Chebotar
Cystic fibrosis (CF) is a common genetic disease, manifested by airway obstruction and chronic respiratory infection. The most prevalent infectious agent in airways of CF patients is Pseudomonas aeruginosa. This study aimed to determine sequence-types, antimicrobial resistance phenotypes and genes defining adaptive antibiotic resistance in P. aeruginosa isolates recovered from CF patients in Russia. In total, 84 P. aeruginosa strains from 64 CF patients were analyzed. Susceptibility to antibiotics was determined by disk diffusion test. Whole-genome sequencing (WGS) was performed on MGISEQ-2000 platform. SPAdes software, Galaxy, ResFinder, PubMLST were used for analysis of WGS data. Examined P. aeruginosa isolates belonged to 53 different sequence-types (STs), including 6 new STs. High-risk epidemic clone ST235 (10%) and clonal CF P. aeruginosa strains ST17, ST242, ST274 (7%) were detected. Non-susceptibility to ticarcillin-clavulanate, cefepime, imipenem was observed in 63%, 12% and 25% of isolates, respectively; to tobramycin - in 24%, to amikacin - in 35%; to ciprofloxacin, levofloxacin - in 35% and 57% of strains, respectively. Multidrug-resistant phenotype was detected in 18% of isolates. In examined strains, genes of beta-lactamases VIM-2 (5 ST235 strains), VEB-1 (two ST2592 strains), GES-1 (1 ST235 strain), PER-1 (1 ST235 strain) were found. Ciprofloxacin-modifying enzyme CrpP gene was detected in 67% of isolates, aminoglycoside-modifying enzymes AAD, ANT, AAC genes - in 7%, 4%, 12% of strains, respectively. P. aeruginosa isolates from CF patients in Russia demonstrate a high clonal diversity, which is similar to other P. aeruginosa infections. The isolates of high-risk clone and clonal CF P. aeruginosa strains are detected.

17 November 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ALA. V. Lyamin
A. V. Lyamin
MZM. O. Zolotov
M. O. Zolotov
OKO. V. Kondratenko
O. V. Kondratenko
EME. A. Maksimova
E. A. Maksimova
DID. D. Ismatullin
D. D. Ismatullin
PBP. V. Bochkareva
P. V. Bochkareva
Introduction. Violation of sputum evacuation in patients with cystic fibrosis leads to the persistence of microorganisms. Most often, the microorganisms are isolated from sputum in patients with cystic fibrosis: Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, etc. For the treatment of infections caused by P. aeruginosa, the following groups of antibiotics are used: aminoglycosides, carbapenems, polymyxins, cephalosporins, fluoroquinolones, inhibitor-protected penicillins and fosfomycin.Aim. To the study is to determine antimicrobial resistance in P. aeruginosa isolated from patients with cystic fibrosis.Materials and methods. An analysis of 87 results of sputum, biomaterial from the posterior wall of the pharynx and nose was made.Results and discussion. Biomaterial was taken from the nasal in 4.6% cases, from the posterior pharyngeal wall in 35.6% and sputum in 59.8%. The lowest level of resistance was registered in strains isolated from the nasal cavity. Microorganisms isolated from the posterior pharyngeal wall showed a higher level of antibiotic resistance. The sensitivity data of sputum isolates were similar to the results from the posterior pharyngeal wall. The highest level of resistance was obtained to aminoglycosides (19.3%) and carbapenems (14.8%). In addition, 12.5% of P. aeruginosa isolates were resistant to sodium colistimethate, 10.2% to fluoroquinolones. The lowest level of insensitivity was found to cephalosporins (5.7%) and protected beta-lactams (4.5%). The revealed trend of decreasing sensitivity, in our opinion, is associated with a greater frequency of antibiotic use.Conclusion. Chronic P. aeruginosa infection in patients with CF contributes to a more severe course of the disease and increases the risk of complications.

22 April 2019 in Siberian Medical Review
Verified
Journal Article
Closed access
NMN. F. Gamaleya National Research Center for Epidemiology and Microbiology
N. F. Gamaleya National Research Center for Epidemiology and Microbiology
OVOlga L. Voronina
Olga L. Voronina
NRNatalia Ryzhova
Natalia Ryzhova
MKM.S. Kunda
M.S. Kunda
EAEkaterina Aksenova
Ekaterina Aksenova
SUSamara State Medical University
Samara State Medical University